Literature DB >> 10811391

The use of adenoviral vectors and ex vivo transduced neurotransplants: towards promotion of neuroregeneration.

B Blits1, P A Dijkhuizen, W T Hermens, L K Van Esseveldt, G J Boer, J Verhaagen.   

Abstract

Regeneration of injured axons following injury depends on a delicate balance between growth-promoting and growth-inhibiting factors. Overexpression of neurotrophin genes seems a promising strategy to promote regeneration. Trophic genes can be overexpressed at the site of injury at the axonal stumps, or at the perikaryal level of the injured neuron. Transduction of the neural cells can be achieved by applying adenoviral vectors, either directly in vivo or-in the case of neurotransplantation as an ex vivo approach. In both cases it would create a more permissive environment for axonal growth and therefore in functional regeneration. In this article, the feasibility of the use of adenoviral vectors in several neuroregeneration models--in particularly in spinal cord lesion models and the biological clock transplantation model--is illustrated. The results show that the adenoviral vectors can be a powerful tool to study the effects of overexpression of genes in an in vivo paradigm of nerve regeneration or nerve outgrowth. The potential use of adenoviral vectors and ex vivo transduced neurotransplants is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811391     DOI: 10.1177/096368970000900204

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  2 in total

1.  Application of a New Gene-Cell Construct Based on the Olfactory Mucosa Escheating Cells Transduced with an Adenoviral Vector Encoding Mature BDNF in the Therapy of Spinal Cord Cysts.

Authors:  E K Karsuntseva; G A Fursa; A O Sosnovtseva; A D Voronova; A V Chadin; A S Semkina; O V Stepanova; V P Chekhonin
Journal:  Bull Exp Biol Med       Date:  2022-03-30       Impact factor: 0.804

Review 2.  Recombinant Adenoviruses for Delivery of Therapeutics Following Spinal Cord Injury.

Authors:  Anastasiia O Sosnovtseva; Olga V Stepanova; Aleksei A Stepanenko; Anastasia D Voronova; Andrey V Chadin; Marat P Valikhov; Vladimir P Chekhonin
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.